Kinek’s online health management tools help heart patient groups
SAINT JOHN, New Brunswick A Canadian cardiovascular patient group has announced the adoption of Kinek Technology’s Wellness Record, to help support heart patients in managing disease and maintaining a healthy lifestyle by utilizing tools online.
Using Kinek’s Wellness Record, Community Cardiovascular Hearts in Motion has been helping patients with heart disease, as well as those at risk. CCHIM has incorporated the online disease management support program into its multidisciplinary regimen which helps patients manage exercise, nutrition, exercise and assess their risk factor after referral by their family physician.
“The Wellness Record provided a tool for our patients to track and improve their behavior while giving the Hearts in Motion team an opportunity to better monitor patients and provide guidance and support between clinic visits,” Nicholas Giacomantonio, CCHIM program medical director said.
Information from the CCHIM estimates that about 30 percent of heart patients stop their recommended exercise routines after six months of leaving the program and most return to poor eating habits shortly thereafter.
But adding the Wellness Record to a patient’s at-home regimen has shown to help cardiovascular patients stay on track, Kinek and the CCHIM said. Reports from these agencies said that after three months, those patients who started using the Wellness Record reported that their low-density lipoproteins, or “bad cholesterol,” levels were lower by 8.9 percent and they lost about 2.5 percent of their body weight. After six months, most patients using the Wellness Record reported their LDL were lowered 14.6 percent and reported weight loss of an average 6.0 percent, reports said.
FDA launches new Web page to provide safety information on prescription drugs
WASHINGTON The Food and Drug Administration announced Wednesday that it had launched a Web page to provide consumers and healthcare professionals with a single source of safety information about prescription drugs.
The page, www.fda.gov/cder/drugsafety.htm, provides links to information in categories such as drug labeling, drugs with risk evaluation and mitigation strategies, regulations and guidance documents and warning letters, import alerts, recalls, market withdrawals and safety alerts.
“By placing Web links to these up-to-date resources on a single page, we’re helping consumers and healthcare professionals find drug safety information faster and easier,” said Dr. Paul Seligman, associate director of safety policy and communication in the FDA’s Center for Drug Evaluation and Research. “This type of communication is aimed at helping consumers and healthcare professionals make well-informed decisions about medication use.”
FDA approves generic version of Epivir
WASHINGTON The Food and Drug Administration has granted tentative approval to Indian drug maker Macleods Pharmaceuticals’ generic version of GlaxoSmithKline’s HIV drug Epivir (lamivudine), FDA records show.
The drug would be available as 150 mg and 300 mg tablets, but cannot be marketed in the United States because of patent protection.
GSK’s patent for lamivudine will expire in 2010. Epivir had sales of $246.85 million in 2007, according to GSK financial records.